NO20054598L - Beta-karboliner anvendbare for behandling av betennelsessykdommer - Google Patents
Beta-karboliner anvendbare for behandling av betennelsessykdommerInfo
- Publication number
- NO20054598L NO20054598L NO20054598A NO20054598A NO20054598L NO 20054598 L NO20054598 L NO 20054598L NO 20054598 A NO20054598 A NO 20054598A NO 20054598 A NO20054598 A NO 20054598A NO 20054598 L NO20054598 L NO 20054598L
- Authority
- NO
- Norway
- Prior art keywords
- inflammatory diseases
- beta
- treating inflammatory
- useful
- carbolines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46146803P | 2003-04-09 | 2003-04-09 | |
PCT/US2004/011080 WO2004092167A1 (en) | 2003-04-09 | 2004-04-09 | Beta-carbolines useful for treating inflammatory disease |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20054598D0 NO20054598D0 (no) | 2005-10-06 |
NO20054598L true NO20054598L (no) | 2005-10-27 |
Family
ID=33299818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054598A NO20054598L (no) | 2003-04-09 | 2005-10-06 | Beta-karboliner anvendbare for behandling av betennelsessykdommer |
Country Status (22)
Country | Link |
---|---|
US (2) | US7727985B2 (zh) |
EP (1) | EP1611134A1 (zh) |
JP (1) | JP2006522824A (zh) |
KR (1) | KR20060006031A (zh) |
CN (1) | CN1802375A (zh) |
AU (1) | AU2004230952A1 (zh) |
BR (1) | BRPI0409263A (zh) |
CA (1) | CA2521300A1 (zh) |
CO (1) | CO5700746A2 (zh) |
CR (1) | CR8042A (zh) |
EA (1) | EA009121B1 (zh) |
EC (1) | ECSP056145A (zh) |
HR (1) | HRP20050926A2 (zh) |
MA (1) | MA27837A1 (zh) |
MX (1) | MXPA05010793A (zh) |
NI (1) | NI200500174A (zh) |
NO (1) | NO20054598L (zh) |
OA (1) | OA13115A (zh) |
RS (1) | RS20050832A (zh) |
TN (1) | TNSN05257A1 (zh) |
WO (1) | WO2004092167A1 (zh) |
ZA (1) | ZA200508198B (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0409263A (pt) | 2003-04-09 | 2006-03-28 | Millennium Pharm Inc | composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita |
KR20070014166A (ko) * | 2004-04-09 | 2007-01-31 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 염증 질환 치료에 유용한 베타-카르볼린 |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
JP5249772B2 (ja) * | 2005-11-22 | 2013-07-31 | メルク・シャープ・アンド・ドーム・コーポレーション | キナーゼの阻害剤として有用な三環式化合物 |
CA2646316C (en) * | 2006-03-15 | 2016-05-24 | Theralogics, Inc. | Methods of treating muscular wasting diseases using nf-kb activation inhibitors |
WO2008002246A1 (en) * | 2006-06-28 | 2008-01-03 | Astrazeneca Ab | A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient. |
AU2007334541A1 (en) * | 2006-12-13 | 2008-06-26 | Gilead Sciences, Inc. | Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (AISTM's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction |
US20090137579A1 (en) * | 2007-10-23 | 2009-05-28 | Millennium Pharmaceuticals, Inc. | Mesylate salt of an IKK inhibitor |
WO2009054965A1 (en) * | 2007-10-23 | 2009-04-30 | Millennium Pharmaceuticals, Inc. | Salts of n- (6-chloro-9h-pyrido [3,4-b] ind0l-8-yl) -4- [2- (2, 6-dimethyl-4-morpholinyl) -2-0x0e thyl] -6, 6-dimethyl-morpholinecarboxamide |
EP2297347B1 (en) | 2008-05-14 | 2017-03-08 | Millennium Pharmaceuticals, Inc. | Methods and kits for monitoring the effects of immunomodulators on adaptive immunity |
EP2366699B1 (en) | 2008-10-02 | 2013-08-07 | Asahi Kasei Pharma Corporation | 8-substituted isoquinoline derivative and use thereof |
RU2012146083A (ru) | 2010-03-30 | 2014-05-10 | Новартис Аг | Ингибиторы ркс для лечения в-клеточной лимфомы с хроническими активным сигнальным каскадом в-клеточного рецептора |
ES2635415T3 (es) * | 2011-03-28 | 2017-10-03 | Sjt Molecular Research, S.L. | Compuestos para el tratamiento del síndrome metabólico |
CN102416014B (zh) * | 2011-09-13 | 2012-11-21 | 河南中医学院 | 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用 |
CN102391323B (zh) * | 2011-10-18 | 2013-09-25 | 首都医科大学 | 四氢-β-咔啉衍生物、其制备方法及其用途 |
KR101646916B1 (ko) | 2015-07-13 | 2016-08-09 | 강원대학교산학협력단 | 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물 |
CN108271369A (zh) | 2015-10-23 | 2018-07-10 | 法尔玛赞公司 | 用于制备色胺及其衍生物的新工艺 |
CN109593089B (zh) * | 2019-01-24 | 2022-01-28 | 西南大学 | 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用 |
CN112824387B (zh) * | 2019-11-21 | 2023-03-21 | 济南尚博生物科技有限公司 | 一种2-甲基烟酸酯及其制备方法和应用 |
CN117510494B (zh) * | 2023-11-07 | 2024-04-19 | 桂林医学院附属医院 | β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2242402T3 (es) * | 1998-08-12 | 2005-11-01 | Pfizer Products Inc. | Inhibidores de tace. |
DE19951360A1 (de) | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
WO2001068648A1 (en) * | 2000-03-15 | 2001-09-20 | Aventis Pharma Deutschland Gmbh | Substituted beta-carbolines with ikb-kinase inhibiting activity |
AU3741801A (en) * | 2000-03-15 | 2001-09-24 | Aventis Pharma Gmbh | Substituted beta-carbolines with ikb-kinase inhibiting activity |
BR0212617A (pt) | 2001-09-19 | 2005-02-09 | Pharmacia Corp | Compostos de pirazolila substituìdo para o tratamento de inflamação |
EP1443927B1 (en) | 2001-11-07 | 2007-01-10 | Millennium Pharmaceuticals, Inc. | Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma |
DE602004016127D1 (de) * | 2003-03-07 | 2008-10-09 | Lilly Co Eli | Antagonisten der opioidrezeptoren |
BRPI0409263A (pt) | 2003-04-09 | 2006-03-28 | Millennium Pharm Inc | composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita |
-
2004
- 2004-04-09 BR BRPI0409263-5A patent/BRPI0409263A/pt not_active IP Right Cessation
- 2004-04-09 CA CA002521300A patent/CA2521300A1/en not_active Abandoned
- 2004-04-09 EP EP04759390A patent/EP1611134A1/en not_active Withdrawn
- 2004-04-09 KR KR1020057019268A patent/KR20060006031A/ko not_active Application Discontinuation
- 2004-04-09 WO PCT/US2004/011080 patent/WO2004092167A1/en active Application Filing
- 2004-04-09 US US10/821,545 patent/US7727985B2/en active Active
- 2004-04-09 MX MXPA05010793A patent/MXPA05010793A/es active IP Right Grant
- 2004-04-09 CN CNA2004800160170A patent/CN1802375A/zh active Pending
- 2004-04-09 EA EA200501584A patent/EA009121B1/ru not_active IP Right Cessation
- 2004-04-09 JP JP2006509889A patent/JP2006522824A/ja active Pending
- 2004-04-09 AU AU2004230952A patent/AU2004230952A1/en not_active Abandoned
- 2004-04-09 OA OA1200500279A patent/OA13115A/en unknown
- 2004-04-09 RS YUP-2005/0832A patent/RS20050832A/sr unknown
-
2005
- 2005-10-06 NO NO20054598A patent/NO20054598L/no not_active Application Discontinuation
- 2005-10-07 NI NI200500174A patent/NI200500174A/es unknown
- 2005-10-07 TN TNP2005000257A patent/TNSN05257A1/en unknown
- 2005-10-11 ZA ZA200508198A patent/ZA200508198B/xx unknown
- 2005-10-12 CR CR8042A patent/CR8042A/es not_active Application Discontinuation
- 2005-10-25 HR HR20050926A patent/HRP20050926A2/hr not_active Application Discontinuation
- 2005-11-04 CO CO05113041A patent/CO5700746A2/es not_active Application Discontinuation
- 2005-11-07 EC EC2005006145A patent/ECSP056145A/es unknown
- 2005-11-09 MA MA28592A patent/MA27837A1/fr unknown
-
2009
- 2009-12-17 US US12/640,335 patent/US20100093713A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HRP20050926A2 (en) | 2006-06-30 |
KR20060006031A (ko) | 2006-01-18 |
AU2004230952A1 (en) | 2004-10-28 |
CO5700746A2 (es) | 2006-11-30 |
OA13115A (en) | 2006-11-10 |
MA27837A1 (fr) | 2006-04-03 |
CN1802375A (zh) | 2006-07-12 |
US20100093713A1 (en) | 2010-04-15 |
ZA200508198B (en) | 2007-01-31 |
US20040235839A1 (en) | 2004-11-25 |
US7727985B2 (en) | 2010-06-01 |
NI200500174A (es) | 2006-04-17 |
EP1611134A1 (en) | 2006-01-04 |
NO20054598D0 (no) | 2005-10-06 |
CR8042A (es) | 2006-05-30 |
JP2006522824A (ja) | 2006-10-05 |
WO2004092167A1 (en) | 2004-10-28 |
TNSN05257A1 (en) | 2007-07-10 |
EA009121B1 (ru) | 2007-10-26 |
WO2004092167A8 (en) | 2006-01-05 |
BRPI0409263A (pt) | 2006-03-28 |
CA2521300A1 (en) | 2004-10-28 |
RS20050832A (en) | 2007-12-31 |
MXPA05010793A (es) | 2005-12-05 |
ECSP056145A (es) | 2006-04-19 |
EA200501584A1 (ru) | 2006-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054598L (no) | Beta-karboliner anvendbare for behandling av betennelsessykdommer | |
NO20062357L (no) | Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer | |
NZ533310A (en) | Benzimidazoles useful as protein kinase inhibitors | |
NO20064763L (no) | Forbindelser og fremgangsmater for behandling av dyslipidemi | |
NO20060670L (no) | N3-substituerte imidazopyridin C-kit inhibitorer | |
NO20060665L (no) | N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer | |
DK1474395T3 (da) | Nicotinamidderivater, der er nyttige som p38-inhibitorer | |
NO20061363L (no) | Pyrazolo- og imidazo- pyrimidinderivater | |
NO20060664L (no) | N-substituerte benzimidazolyl C-kit inhibitorer | |
ATE433967T1 (de) | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation | |
NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
EA200600317A1 (ru) | Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты) | |
NO20084912L (no) | Bisykliske derivater som CETP-inhibitorer | |
MY142018A (en) | Thiophene derivatives as chk 1 inihibitors | |
CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
NO20064894L (no) | Beta-karboliner anvendbare for behandling av inflammatoriske sykdommer | |
NO20071574L (no) | Arylsulfonylstilbenderivater for behandling av insomni og beslektede tilstander. | |
NO20062900L (no) | Nye forbindelser | |
NO20054340L (no) | Nye sammenkoplede heterocykler og deres anvendelse | |
NO20044526L (no) | Hemisterlinderivater og anvendelser derav | |
ATE452896T1 (de) | C3-cyanoepothilonderivate | |
NO20063220L (no) | Tricykliske imidazopyridiner for anvendelse som gastriske sekresjonsinhibitorer | |
NO20072060L (no) | 2-acylaminotiazolderivater | |
BR0318521A (pt) | arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados | |
DK1670768T3 (da) | Forbindelser og fremgangsmåder til at behandle dyslipidæmi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |